SSaama AI Agents

Saama AI Agents are modular clinical development agents that review trial data, monitor studies, flag anomalies and generate submission datasets such as ADaM packages. They suit pharma and biotech sponsors running many studies who want to add agents to clinical data management, biostatistics and operations without replacing their systems. Saama brings a long record in clinical data: reporting in 2021 credited its platform with cutting about a month from data review in Pfizer’s COVID-19 vaccine trial.

Visibility is where Saama has the most room to improve. Pricing is shared by quote, agent-level performance figures are few so far and the agent pages do not list security certifications, so buyers rely on demos and pilots. We rate it 7.3/10 on our scale. This review is based on Saama’s published announcements and product pages and on news coverage; we have not used the product.

A Clinical Data Company’s Track Record in Figures

Saama is an established clinical data company, so the numbers below are mostly about the company and its track record rather than agent benchmarks. Each was checked on the source page.

For a buyer, the Pfizer result and the pharma investors matter most. They show that Saama’s underlying data platform has handled high-stakes trials and that large sponsors were willing to invest in it. They do not measure the new agents directly, so ask for agent-level results from comparable studies. A credible pilot should report hours saved per study, query cycle times and the share of agent outputs that needed correction.

Saama’s own framing is useful context: it cites the MIT finding on failed AI pilots to argue for agents that slot into existing workflows one at a time. That suits risk-averse clinical organizations, and it means value builds as more agents are added.

An Agentic AI Framework Built Around Single Clinical Tasks

Saama groups its agents under an Agentic AI Framework. Each agent is trained for a specific clinical task, connects through APIs and plugs into Saama’s AI operating system, which Saama calls AIOS, or into a sponsor’s existing systems.

Operational Agents

1. Assess. Agents read study data and evaluate each situation in its clinical context.
2. Act. They review data, monitor trial progress, detect anomalies and resolve routine tasks.
3. Report. Outcomes go back to human experts, who decide on anything that needs judgment.
4. Extend. Sponsors add agents over time, such as patient narrative generation or inclusion and exclusion criteria drafting, without disrupting current workflows.

Submission Programming

ADaM Navigator automates generation of analysis data model packages, including specifications, programs and define.xml, replacing a manual, step-by-step workflow for statistical programmers. SDTM Navigator works alongside it to help programmers produce submission-ready deliverables. These are the agents Saama highlighted when it won its 2026 award.

Where the Agents Fit in a Study

Saama pitches its agents as covering the lifecycle from study start to submission. At the start, drafting agents can propose inclusion and exclusion criteria for protocol teams to refine. During conduct, operational agents review incoming data, monitor trial progress and flag anomalies so data managers spend their time on the items that need judgment. Toward the end, patient narrative generation and the ADaM and SDTM tools target the programming and writing that usually pile up before database lock and submission. A sponsor does not need every stage at once; the modular design is meant to let teams begin wherever the backlog hurts most.

Why Saama Went Modular

When it launched the agents, Saama pointed to an MIT report finding that 95% of enterprise generative AI pilots fail, and blamed poor integration, limited adaptability and generic tools. Its answer was agents trained for single clinical tasks that plug into existing workflows, plus bespoke agents with continuous training for sponsors whose processes differ. For buyers, this means a smaller first commitment, but also that the full value depends on how many agents are eventually adopted and how well they are integrated.

Wider Product Family

Saama’s site also lists Data Hub, Smart Data Quality, Smart Medical Coding, Operational Insights, Patient Insights, an Agentic Document Generator and its BRAIN products for statistical computing and SDTM work. Buyers should ask which of these are packaged as agents today. Saama also runs Astraa, a sister company that serves banking, insurance and the public sector.

Data Managers and Statisticians Keep Regulatory Sign-Off

Saama describes partial autonomy with humans in the loop. Clinical data managers, statisticians and medical reviewers still approve data decisions, validate programming outputs and sign off on anything that goes to regulators. Agents reduce the review and programming workload rather than replacing accountable staff.

Per-Agent Licensing With No Published Rates

Saama does not publish prices. Agents are licensed by its sales team, and the model is built around modular adoption.

Contract Terms Worth More Attention Than the Price

Because Saama quotes every deal, the contract terms deserve as much attention as the price. Ask whether licensing is per agent, per study or enterprise-wide, and what happens to cost as more agents are added. Confirm which agents are generally available and which would be built for you. Request validation documentation for regulated use, details on where study data is processed and whether it is used to improve shared models, and reference customers running the same agents on comparable studies. Finally, agree in writing how outputs such as ADaM programs can be exported and maintained if you leave.

Scoping a First Agent at a Mid-Size Biotech

Without list prices, scenarios have to focus on scope and effort rather than dollars.

Mid-size biotech with a few active studies. Starting with one agent, such as data review or ADaM Navigator, limits integration work and makes the pilot easy to measure: compare programming hours or query resolution time on one study against the last comparable study.

Large sponsor with many trials. Chaining agents across data review, monitoring and submission programming is where Saama’s modular model is designed to pay off, but expect a longer implementation and a larger contract.

Hidden and variable costs. Integration with existing EDC and data systems, validation work required in regulated environments, and training bespoke agents should all be in scope before signing. Saama does not publish pricing terms, so negotiate renewal caps up front.

Saama AI Agents Compared With Medable AI Agents, IQVIA.ai and Veeva AI Agents

These are the closest clinical development alternatives on our site. All are quote-only, so the differences come down to scope and lock-in.

All four are quote-only, so the comparison that matters most is lock-in. Veeva and IQVIA agents deliver the most value when you already buy their platforms or services, while Saama says its agents can plug into a sponsor’s existing systems through APIs. For sponsors with a mixed stack of data, statistics and operations tools, that independence is a practical advantage, provided the integration and validation work is scoped carefully before the contract is signed.

Saama’s distinguishing point is depth in clinical data management and statistical programming, plus the option to add agents without replacing systems. Medable leans toward trial operations, IQVIA toward its own data and services, and Veeva toward its Vault applications. For regulatory writing rather than data, see Weave Bio. More options are on our life sciences agents page.

Clinical Data Management and Biostatistics Groups

• Clinical data management teams: data review and anomaly detection agents target their daily workload.
• Biostatistics and programming groups: ADaM Navigator and SDTM Navigator automate submission dataset work.
• Sponsors with mixed systems: agents connect through APIs rather than requiring a platform switch.
• Risk-averse organizations: starting with one agent keeps a pilot small and measurable, and Saama’s human-in-the-loop design fits quality systems that require documented review.
• Enterprise buyers comparing vendors: see our enterprise agents for broader options.

Small Sponsors, Discovery Labs and Veeva Shops

• Small sponsors wanting self-serve tools: there is no trial or published price.
• Discovery research teams: Biomni Lab or Kosmos fit lab science better.
• Veeva-standardized companies: native Veeva agents may be simpler to adopt.
• Buyers who need published benchmarks: Saama has shared few agent-level figures so far.
• Teams needing regulatory document drafting: a specialist such as Weave Bio covers INDs and agency questions.
• Sponsors with one or two small studies: the integration and validation effort of an enterprise agent program may outweigh the time saved at low volume.

Agent Metrics, Validation Documents and Ownership

• Agent-level results: the Pfizer result predates the agents; ask for agent results from comparable studies.
• Security and validation: the agent pages do not list certifications; request GxP, 21 CFR Part 11 and data protection documentation.
• Product naming: many modules are listed on Saama’s site without detail, so confirm what is available today.
• Implementation effort: integration and validation in a regulated environment take time.
• Ownership: Carlyle-led funds took a majority stake in 2021, and the CEO has changed since then, so ask about roadmap commitments.
• Human review: partial autonomy means staff still validate outputs before they reach regulators.

AI Breakthrough Award and Saama’s 2025 Moves

On June 25, 2026, Saama won AI-based Life Sciences Solution of the Year in the AI Breakthrough Awards, highlighting its Agentic AI Framework and its ADaM and SDTM Navigator tools. On September 29, 2025, Saama introduced modular and adaptive AI agents for clinical development, built on its agentic platform and designed to work with its Digital Study Platform or existing systems.

A Pilot Makes Sense for Heavy Data Workloads

For pharma and biotech sponsors with heavy clinical data and programming workloads, Saama AI Agents are worth a pilot. They score 7.3/10 on our scale. The modular approach lets you start with one agent, the submission programming tools address a well-defined bottleneck, and Saama’s history with large trials and pharma investors gives it more credibility than most new entrants.

The score reflects how much a buyer can see before a sales process: pricing is shared by quote, agent metrics are few, the agent pages do not list security certifications and public ratings have not appeared. Publishing more of that would help. Pick one study and one agent, agree success measures with Saama in advance, and review validation and data terms with your quality team. Programming-heavy teams will likely see results soonest, since ADaM package generation is a contained task with outputs that are easy to check against what programmers produced by hand. Operational agents for data review and monitoring are harder to measure but touch more staff, so they are the better second step once the first pilot has proved itself. Compare more options on our life sciences agents page.

Clinical Teams’ Questions on Saama’s Agents

How Much Do Saama AI Agents Cost?

Saama does not publish prices. Agents are quoted by its sales team and can be licensed individually, as workflows or as bespoke builds.

What Is ADaM Navigator?

ADaM Navigator is a Saama tool that automates generation of ADaM packages, including specifications, programs and define.xml. It works with SDTM Navigator to help statistical programmers produce submission-ready deliverables.

Do Saama Agents Replace Clinical Data Managers?

No. Saama describes partial autonomy with humans in the loop. Agents review data, monitor trials and flag anomalies, then report to experts who make decisions.

Do I Need the Saama Platform to Use the Agents?

No. Saama says the agents can integrate with its Digital Study Platform or with a sponsor’s existing systems through APIs.

What Did Saama Do for Pfizer?

Saama partnered with Pfizer in 2020, and its AI was reported to have cut about a month from research time for the COVID-19 vaccine trial data review. That work used Saama’s data platform before the current agents launched.